Evofem Biosciences Files 8-K
Ticker: EVFM · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1618835
Sentiment: neutral
Topics: disclosure, financials
Related Tickers: EVFM
TL;DR
EVFM filed an 8-K on 7/18 for Reg FD disclosure & financials.
AI Summary
Evofem Biosciences, Inc. filed an 8-K on July 18, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits as of July 17, 2024. The company, formerly known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates important disclosures and financial updates from Evofem Biosciences, Inc. that could affect investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains disclosures and financial information without immediate, significant operational or market-moving news.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- July 17, 2024 (date) — Date of earliest event reported
- July 18, 2024 (date) — Filing date
- San Diego, California (location) — Company headquarters
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of this disclosure are not provided in the provided text snippet.
What financial statements and exhibits are included in this filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these documents is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 17, 2024.
What is the principal executive office address of Evofem Biosciences, Inc.?
The principal executive office address is 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What was Evofem Biosciences, Inc. formerly known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-07-18 08:15:48
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share EVFM OTCQB Indicate by
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 32KB
- ex99-1_001.jpg (GRAPHIC) — 67KB
- ex99-1_002.jpg (GRAPHIC) — 375KB
- ex99-1_003.jpg (GRAPHIC) — 92KB
- ex99-1_004.jpg (GRAPHIC) — 67KB
- ex99-1_005.jpg (GRAPHIC) — 71KB
- ex99-1_006.jpg (GRAPHIC) — 72KB
- ex99-1_007.jpg (GRAPHIC) — 73KB
- ex99-1_008.jpg (GRAPHIC) — 41KB
- ex99-1_009.jpg (GRAPHIC) — 56KB
- ex99-1_010.jpg (GRAPHIC) — 97KB
- ex99-1_011.jpg (GRAPHIC) — 58KB
- ex99-1_012.jpg (GRAPHIC) — 99KB
- ex99-1_013.jpg (GRAPHIC) — 85KB
- ex99-1_014.jpg (GRAPHIC) — 77KB
- ex99-1_015.jpg (GRAPHIC) — 79KB
- ex99-1_016.jpg (GRAPHIC) — 71KB
- ex99-1_017.jpg (GRAPHIC) — 98KB
- ex99-1_018.jpg (GRAPHIC) — 74KB
- ex99-1_019.jpg (GRAPHIC) — 63KB
- ex99-1_020.jpg (GRAPHIC) — 79KB
- ex99-1_021.jpg (GRAPHIC) — 72KB
- ex99-1_022.jpg (GRAPHIC) — 72KB
- ex99-1_023.jpg (GRAPHIC) — 71KB
- ex99-1_024.jpg (GRAPHIC) — 43KB
- 0001493152-24-028280.txt ( ) — 3065KB
- evfm-20240717.xsd (EX-101.SCH) — 3KB
- evfm-20240717_lab.xml (EX-101.LAB) — 33KB
- evfm-20240717_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: July 17, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer